EMEA-002566-PIP01-19
Key facts
| Active substance |
(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (SAR442168)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0310/2020
|
| PIP number |
EMEA-002566-PIP01-19
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Sanofi Winthrop Industrie
Email: contact-us@sanofi.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|